Treatment Response and Complications after Intradetrusor OnabotulinumtoxinA Injection in Male Patients with Idiopathic Overactive Bladder Syndrome

Arrom, Laura Mateu; Ferrer, Olga Mayordomo; Rubio, Laia Sabiote; Ruiz, Cristina Gutiérrez; Barea, Virginia Martínez; Redorta, Joan Palou; Errando‐Smet, Carlos

doi:10.1097/ju.0000000000000525

Cited by 17 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, urodynamic confirmation of DO may not be necessary, although guidelines and many clinicians would advocate their use to determine other factors such as mixed incontinence, outflow obstruction, and poor compliance, which will help in patient selection and counselling. Mateu Arrom et al [16] found that a higher BOOI is a predictor of poor response in their cohort of male patients, which backs up the fact that prior urodynamic assessment may be necessary in order to select patients. It remains to be seen whether office evaluation, bladder diaries, and validated questionnaires can replace the need for urodynamic assessment prior to BTX-A treatment entirely.…”

Section: Discussionmentioning

confidence: 94%

“…Receiver operator characteristic curve analysis suggested that a PIP1 of 50 in women (sensitivity 0.83, specificity 0.70, area under the curve 0.822) and a BCI of 120 in men (sensitivity 0.7, specificity 0.79, area 0.879) might predict the need for CISC. Mateu Arrom et al [16] found a higher BOOI to be a predictor of CISC in males. GRADE working group grades of evidence: here we assess the certainty of evidence on mean outcome importance.…”

Section: Urodynamic Parametersmentioning

confidence: 97%

“…Treatment response and complications after intradetrusor onabotulinumtoxinA injection in male patients with idiopathic overactive bladder syndrome 2020 Mateu Arrom et al [16] Cohort study R 146…”

Section: Oxford Level Of Evidencementioning

confidence: 99%

“…Of the studies that found some urodynamic parameters to be significant, Sahai et al [15] reported higher baseline maximum detrusor pressure (MDP) to be a predictor of poor response (MDP mean AE SD 138.0 AE 30.7 vs 74.4 AE 32.6; p = 0.0028, in nonresponders group vs responders group). Mateu Arrom et al [16] reported that a higher bladder outlet obstruction index (BOOI) was a predictor of poor response using a score of 3 or 4 on the Treatment Benefit Scale (3 meaning no improvement in symptoms and 4 meaning worsening of symptoms). Schmid et al [17] observed both low pretreatment detrusor compliance (<10 ml/cmH 2 O) and maximum cystometric bladder capacity (MCBC) of <100 ml, in eight of 100 patients who were deemed to be poor responders clinically.…”

Section: Urodynamicsmentioning

confidence: 99%

“…The certainty of evidence for this outcome was downgraded for risk of bias, inconsistency, and imprecision. c Six studies: Sahai et al [15], Abrar et al [11], Kuo et al [19], Mateu Arrom et al [16], Osborn et al [20], and Hsiao et al [5]. The certainty of evidence for this outcome was downgraded for risk of bias, inconsistency, and imprecision.…”

Section: Urodynamic Parametersmentioning

confidence: 99%

See 4 more Smart Citations

Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic Review

Abrar

Pindoria

Malde

et al. 2021

European Urology Focus

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 94%

Section: Urodynamic Parametersmentioning

confidence: 97%

Section: Oxford Level Of Evidencementioning

confidence: 99%

Section: Urodynamicsmentioning

confidence: 99%

Section: Urodynamic Parametersmentioning

confidence: 99%

See 3 more Smart Citations

Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic Review

Abrar

Pindoria

Malde

et al. 2021

European Urology Focus

View full text Add to dashboard Cite

Botulinum toxin for treating overactive bladder in men: A systematic review

Truzzi

Lapitan

Truzzi

et al. 2022

Neurourology and Urodynamics

View full text Add to dashboard Cite

Purpose We sought to systematically review the literature on the use of botulinum toxin (BTX‐A) injections in the bladder to treat overactive bladder (OAB) in men. Materials and methods A systematic review was performed to identify clinical trials on efficacy and safety of BTX‐A injections in the detrusor for treatment of OAB in men published from inception to October 2020. Quality assessment was performed using the Cochrane Collaboration's tool for assessing risk of bias and study characteristics were extracted by two reviewers independently. Results After screening 75 abstracts, 12 trials were included in the qualitative synthesis, of which 6 were conducted exclusively in men (mean age: 66.7 years). Only two were randomized controlled studies and the remaining were observational studies, mostly case series. Total number of participants in each study ranged from 28 to 146. Therapeutic response to intravesical BTX‐A injection was assessed differently across the studies, which used quality‐of‐life symptom questionnaires and voiding diary parameters. Urodynamics findings were reported separately for men before and after intravesical injection of BTX‐A in two studies only. Pooling of outcome data was possible with adverse events reported after BTX‐A by seven studies, which showed urinary tract infection, urinary retention, increased postvoid residual, de novo interstitial cystitis, and hematuria rates of 29.8%, 20.0%, 37.3%, 28.3%, and 12.4%, respectively. Conclusions Limited information regarding the efficacy and safety of BTX‐A bladder injections for male OAB from relatively low evidence is available. Further research is needed to better understand the risk‐benefit profile of BTX‐A in the male population.

show abstract

Treatment of overactive bladder in men: Is it really different?

Shapiro

Brucker

2022

Neurourology and Urodynamics

View full text Add to dashboard Cite

Introduction Overactive bladder (OAB) in men is a topic that is gaining increasing attention as there is a wider understanding that OAB is not a female condition. There are several treatments; however, data in male populations are lacking compared to female cohorts. The high likelihood of concomitant benign prostatic hyperplasia (BPH) and benign prostatic obstruction (BPO) adds to the complexity of the treatment algorithm. The overlap in urinary storage symptoms also makes the interpretation of the literature challenging. Methods Articles that evaluated men with OAB and men with OAB and BPH/BPO were evaluated and assessed. Results Behavioral interventions can offer a significant benefit to male patients with OAB. Medical therapies that have been studied in men with OAB include anticholinergics, beta‐3 agonists, and phosphodiesterase‐5 inhibits. These agents can be offered in addition to alpha‐blockers for men with coexisting BPH/BPO. The literature on Onabotulinumtoxin‐A and neuromodulation modulation in the male population is growing and shows promising results. Conclusion Male OAB is complex; however, there is a growing body of literature to help guide treatments. Many treatments are available and they have shown considerable success.

show abstract

Treatment Response and Complications after Intradetrusor OnabotulinumtoxinA Injection in Male Patients with Idiopathic Overactive Bladder Syndrome

Cited by 17 publications

References 0 publications

Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic Review

Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic Review

Botulinum toxin for treating overactive bladder in men: A systematic review

Treatment of overactive bladder in men: Is it really different?

Contact Info

Product

Resources

About